低前列腺特异性抗原预示高级别而非低/中级别前列腺癌更差结局
基于英格兰国家前列腺癌审计数据库的回顾性队列研究纳入102,089例临床局限性前列腺癌男性,比较低/中级别与高级别前列腺癌中PSA与前列腺癌特异性死亡(PCSM)的关联。高级别前列腺癌中PSA≤5者4年PCSM高于PSA 5.1-10者(EBRT组HR 1.96,95%CI 1.15-3.34;未接受根治性局部治疗组HR 1.99,95%CI 1.33-2.98)。限制性立方样条回归显示高级别前列腺癌中PSA与PCSM呈非线性关联,而低/中级别呈线性关联。
要点
- 高级别前列腺癌中PSA≤5者4年PCSM高于PSA 5.1-10者(EBRT组HR 1.96,95%CI 1.15-3.34)
- 未接受根治性局部治疗的高级别前列腺癌中PSA≤5者4年PCSM高于PSA 5.1-10者(HR 1.99,95%CI 1.33-2.98)
- 高级别前列腺癌中PSA与PCSM呈非线性关联,低/中级别呈线性关联
核心结论
- 在M0期接受EBRT治疗的前列腺癌中,低PSA/高级别组合的PCSM高于高级别且PSA处于中等水平者。
- 高级别前列腺癌中PSA与PCSM呈非线性关联,而低/中级别呈线性关联。
- 这证实低PSA分泌的高级别前列腺癌生物学更具侵袭性,治疗后结局更差。
研究设计与样本
- 回顾性队列研究,使用英格兰国家前列腺癌审计数据库,纳入2014年至2018年间接受外照射放疗(EBRT)、EBRT联合近距离放疗 boost(EBRT + BT)、根治性前列腺切除术或未接受根治性局部治疗的男性。
- 共纳入102,089例男性,其中71,138例为低/中级别前列腺癌,22,425例为高级别前列腺癌。
主要发现
- 高级别前列腺癌中,接受EBRT者PSA≤5的4年PCSM高于PSA 5.1-10者(HR 1.96,95%CI 1.15-3.34)。
- 高级别前列腺癌中,未接受根治性局部治疗者PSA≤5的4年PCSM高于PSA 5.1-10者(HR 1.99,95%CI 1.33-2.98)。
- 限制性立方样条回归显示高级别前列腺癌中PSA与PCSM呈非线性关联,低/中级别呈线性关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The relationship between prostate-specific antigen (PSA) and prostate cancer (PCa) grade was traditionally thought to be linear but recent reports suggest this is not true in high-grade cancers. We aimed to compare the association between PSA and PCa-specific mortality (PCSM) in clinically localised low/intermediate and high-grade PCa. SUBJECTS/PATIENTS AND METHODS: Retrospective cohort study using the National Prostate Cancer Audit database in England of men treated with external beam radiotherapy (EBRT), EBRT and brachytherapy boost (EBRT + BT), radical prostatectomy or no radical local treatment between 2014 and 2018. Multivariable competing-risk regression was used to examine the association between PSA, Gleason, and PCSM. Multivariable restricted cubic spline regression was used to explore the non-linear associations of PSA and PCSM. RESULTS: 102,089 men were included, of whom 71,138 had low/intermediate-grade and 22,425 had high-grade PCa. In high-grade, 4-year PCSM was higher with PSA ≤5 than PSA 5.1-10 for men treated with EBRT (hazard ratio 1.96 (95% confidence interval 1.15-3.34) or no radical local treatment (hazard ratio 1.99 (95% confidence interval 1.33-2.98). Restricted cubic spline regression showed that PSA and PCSM have a non-linear association in high-grade but a linear association in low/intermediate-grade PCa. CONCLUSION: The low-PSA/high-grade combination in M0 PCa treated with EBRT has a higher PCSM than those with high-grade and intermediate PSA levels. In high-grade disease, the PSA association was non-linear; by contrast, low/intermediate-grade had a linear relationship. This confirms a more aggressive biology in low PSA secreting high-grade PCa and a worse outcome following treatment.
引用
- Fankhauser CD, Parry MG, Ali A, et al. A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer. Eur J Cancer. 2022. PMID: 36641896. doi:10.1016/j.ejca.2022.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。